Aptus Clinical signs Clinical Development Agreement with Taiwan based OBI Pharma

15th January 2015

We are pleased to announce that we have entered into an agreement with OBI Pharma to support their physicians and scientists in the design of a translational medicine study to support the development of their breast cancer vaccine OBI-822.

We are honoured that OBI has placed their trust in our team of translational scientists, physicians and clinical operations experts to support them in the design and development of this exciting immuno-oncology project.This agreement marks a significant milestone for Aptus Clinical in our mission to broaden the support we provide to Biotechs globally in the design, conduct and delivery of early phase oncology studies in the UK. The flexibility, quality and experience of our expert team combined with collaborative input from world-leading academic centres provides a compelling service offering to our expanding client base.